Teva Pharma Industries Stock Performance
| TEVA Stock | USD 16.18 0.08 0.50% |
The entity has a beta of -0.53, which indicates possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Teva Pharma are expected to decrease at a much lower rate. During the bear market, Teva Pharma is likely to outperform the market. At this point, Teva Pharma Industries has a negative expected return of -0.52%. Please make sure to validate Teva Pharma's downside variance, as well as the relationship between the kurtosis and day median price , to decide if Teva Pharma Industries performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Very Weak
Weak | Strong |
Over the last 90 days Teva Pharma Industries has generated negative risk-adjusted returns adding no value to investors with long positions. Despite unfluctuating performance in the last few months, the Stock's basic indicators remain somewhat strong which may send shares a bit higher in April 2025. The current disturbance may also be a sign of long term up-swing for the company investors. ...more
Actual Historical Performance (%)
One Day Return 0.5 | Year To Date Return (24.04) | Ten Year Return (73.59) | All Time Return 1.7 K |
Last Split Factor 2:1 | Dividend Date 2017-12-12 | Ex Dividend Date 2017-11-27 | Last Split Date 2004-07-01 |
1 | Acquisition by Eliyahu Kalif of 183169 shares of Teva Pharma subject to Rule 16b-3 | 01/28/2025 |
2 | Disposition of 161655 shares by Richard Francis of Teva Pharma subject to Rule 16b-3 | 02/14/2025 |
3 | Multiple Sclerosis Market Size to Hit USD 43.40 Billion by 2032, Growing at a CAGR of 7.00 percent - SNS Insider | 02/19/2025 |
4 | Teva and Medincell Announce FDA Acceptance of Supplemental New Drug Application for UZEDY Extended-Release Injectable Suspension as a Treatment for Patients wit... | 02/25/2025 |
5 | Disposition of 6450 shares by Richard Francis of Teva Pharma at 15.5576 subject to Rule 16b-3 | 03/04/2025 |
6 | Allergic Conjunctivitis Market Global Report 2025-2033 Developments in Corticosteroids and Antihistamines Fueling Growth | 03/10/2025 |
7 | Teva Pharmaceutical Industries Limited Stake Raised by Achmea Investment Management B.V. | 03/13/2025 |
8 | Teva Upgrades Its 4PL Model, Enhancing Medicine Accessibility for Patients with Kerry Pharma | 03/14/2025 |
9 | Teva Pharmaceutical Industries Sees 14 percent Stock Price Rise With FDA Acceptance Of New Drug Application | 03/18/2025 |
10 | Here Are Billionaire Stanley Druckenmillers 5 Biggest Stock Holdings | 03/19/2025 |
11 | Teva Pharmaceutical Industries Ltd to Discuss The Duvakitug Positive Phase 2b ... | 03/20/2025 |
12 | Teva Pharmaceutical Induss Options A Look at What the Big Money is Thinking | 03/21/2025 |
13 | Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys 4,328 Shares of Teva Pharmaceutical Industries Limited | 03/24/2025 |
| Begin Period Cash Flow | 3.2 B |
Teva |
Teva Pharma Relative Risk vs. Return Landscape
If you would invest 2,262 in Teva Pharma Industries on December 25, 2024 and sell it today you would lose (644.00) from holding Teva Pharma Industries or give up 28.47% of portfolio value over 90 days. Teva Pharma Industries is currently does not generate positive expected returns and assumes 2.867% risk (volatility on return distribution) over the 90 days horizon. In different words, 25% of stocks are less volatile than Teva, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Teva Pharma Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Teva Pharma's investment risk. Standard deviation is the most common way to measure market volatility of stocks, such as Teva Pharma Industries, and traders can use it to determine the average amount a Teva Pharma's price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = -0.1831
| Best Portfolio | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| Negative Returns | TEVA |
Estimated Market Risk
| 2.87 actual daily | 25 75% of assets are more volatile |
Expected Return
| -0.52 actual daily | 0 Most of other assets have higher returns |
Risk-Adjusted Return
| -0.18 actual daily | 0 Most of other assets perform better |
Based on monthly moving average Teva Pharma is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Teva Pharma by adding Teva Pharma to a well-diversified portfolio.
Teva Pharma Fundamentals Growth
Teva Stock prices reflect investors' perceptions of the future prospects and financial health of Teva Pharma, and Teva Pharma fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Teva Stock performance.
| Return On Equity | -0.28 | ||||
| Return On Asset | 0.0509 | ||||
| Profit Margin | (0.1) % | ||||
| Operating Margin | 0.21 % | ||||
| Current Valuation | 32.87 B | ||||
| Shares Outstanding | 1.15 B | ||||
| Price To Earning | 15.67 X | ||||
| Price To Book | 3.45 X | ||||
| Price To Sales | 1.12 X | ||||
| Revenue | 16.54 B | ||||
| Gross Profit | 8.06 B | ||||
| EBITDA | (303 M) | ||||
| Net Income | (1.96 B) | ||||
| Cash And Equivalents | 2.22 B | ||||
| Cash Per Share | 2.00 X | ||||
| Total Debt | 18.08 B | ||||
| Debt To Equity | 2.27 % | ||||
| Current Ratio | 0.99 X | ||||
| Book Value Per Share | 4.74 X | ||||
| Cash Flow From Operations | 1.25 B | ||||
| Earnings Per Share | (1.45) X | ||||
| Market Capitalization | 18.54 B | ||||
| Total Asset | 39.33 B | ||||
| Retained Earnings | (15.17 B) | ||||
| Working Capital | (244 M) | ||||
| Current Asset | 18.4 B | ||||
| Current Liabilities | 13.01 B | ||||
About Teva Pharma Performance
By analyzing Teva Pharma's fundamental ratios, stakeholders can gain valuable insights into Teva Pharma's financial health, operational efficiency, and overall profitability, helping them make informed investment and management decisions. For instance, if Teva Pharma has a high ROA and ROE, it suggests that the company is efficiently using its assets and equity to generate substantial profits, making it an attractive investment. Conversely, if Teva Pharma has a low ROA and ROE, it may indicate underlying issues in asset and equity management, signaling a need for operational improvements.
| Last Reported | Projected for Next Year | ||
| Days Of Inventory On Hand | 129.41 | 143.34 | |
| Return On Tangible Assets | (0.08) | (0.08) | |
| Return On Capital Employed | (0.01) | (0.01) | |
| Return On Assets | (0.04) | (0.04) | |
| Return On Equity | (0.31) | (0.29) |
Things to note about Teva Pharma Industries performance evaluation
Checking the ongoing alerts about Teva Pharma for important developments is a great way to find new opportunities for your next move. Stock alerts and notifications screener for Teva Pharma Industries help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Teva Pharma generated a negative expected return over the last 90 days | |
| Teva Pharma Industries currently holds 18.08 B in liabilities with Debt to Equity (D/E) ratio of 2.27, implying the company greatly relies on financing operations through barrowing. Teva Pharma Industries has a current ratio of 0.97, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Note, when we think about Teva Pharma's use of debt, we should always consider it together with its cash and equity. | |
| The entity reported the previous year's revenue of 16.54 B. Net Loss for the year was (1.96 B) with profit before overhead, payroll, taxes, and interest of 8.06 B. | |
| About 60.0% of Teva Pharma shares are owned by institutional investors | |
| Latest headline from thelincolnianonline.com: Commonwealth of Pennsylvania Public School Empls Retrmt SYS Buys 4,328 Shares of Teva Pharmaceutical Industries Limited |
- Analyzing Teva Pharma's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Teva Pharma's stock is overvalued or undervalued compared to its peers.
- Examining Teva Pharma's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Teva Pharma's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Teva Pharma's management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Teva Pharma's stock. These opinions can provide insight into Teva Pharma's potential for growth and whether the stock is currently undervalued or overvalued.
Complementary Tools for Teva Stock analysis
When running Teva Pharma's price analysis, check to measure Teva Pharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Teva Pharma is operating at the current time. Most of Teva Pharma's value examination focuses on studying past and present price action to predict the probability of Teva Pharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Teva Pharma's price. Additionally, you may evaluate how the addition of Teva Pharma to your portfolios can decrease your overall portfolio volatility.
| USA ETFs Find actively traded Exchange Traded Funds (ETF) in USA | |
| Portfolio Optimization Compute new portfolio that will generate highest expected return given your specified tolerance for risk | |
| Equity Search Search for actively traded equities including funds and ETFs from over 30 global markets | |
| Price Exposure Probability Analyze equity upside and downside potential for a given time horizon across multiple markets | |
| Options Analysis Analyze and evaluate options and option chains as a potential hedge for your portfolios | |
| Portfolio File Import Quickly import all of your third-party portfolios from your local drive in csv format | |
| Portfolio Center All portfolio management and optimization tools to improve performance of your portfolios | |
| Stock Tickers Use high-impact, comprehensive, and customizable stock tickers that can be easily integrated to any websites |